#USA #Philadelphia #Oxford #Clario #Opal

Clario and the University of Oxford's NeuroMetrology Lab Join Forces

In an exciting development in the realm of medical technology, Clario, a frontrunner in clinical trial data solutions, has teamed up with the prestigious University of Oxford's NeuroMetrology Lab. This partnership aims to significantly enhance Parkinson's disease research through the use of the Opal® wearable sensor system. As clinical trials progress, the collaboration promises to revolutionize how motor symptoms and disease progression are measured, potentially transforming clinical outcomes for patients.

Advancing Clinical Trials

Clario recently announced the enrollment of its first participant in this pioneering collaboration, under the guidance of Professor Chrystalina Antoniades from the NeuroMetrology Lab. The goal is to improve clinical trial endpoints by offering better identification of how the disease progresses and movement-based measurements. This marks a crucial step in the quest for more effective treatments for Parkinson's disease (PD), a neurodegenerative disorder that significantly affects motor skills and quality of life.

Precision Through Wearable Technology

The Opal® wearable sensor is designed to collect extensive and objective movement data. Its capability to operate with single or multiple sensor setups allows for subtle yet significant detection of changes in gait, balance, and overall mobility. This level of precision can surpass traditional assessment methods, leading to a more accurate monitoring of Parkinson's disease progression. Moreover, the NeuroMetrology Lab's innovative approach leverages Opal's advanced movement analysis features to foresee critical events such as falls, which are among the leading causes of disability for PD patients.

Recent studies conducted by Professor Antoniades' team highlight the remarkable predictive ability of this technology. For instance, a simple three-minute assessment in an office setting could forecast the risk of falls in patients with Parkinson's with an astounding accuracy rate of 84% to 92% for up to two years in advance, and around 78% up to five years in advance. This involves the power and potential of movement analysis, fundamentally altering how researchers and clinicians can manage Parkinson's disease more proactively.

Impacting Patient Outcomes

Ellen Street, Clario's Executive Vice President and General Manager of Digital Physiology, expressed her enthusiasm about the partnership, stating, "Our collaboration with Professor Antoniades and her team is an exhilarating advancement in Parkinson's research." By integrating Opal's capabilities, this research can enhance tracking of disease progression and deepen the understanding of therapeutic impacts on Parkinson’s patients. Clario's mission aligns perfectly with this initiative, aiming to leverage better evidence for improved patient outcomes.

On the academic side, Professor Antoniades voiced her excitement as well, emphasizing the collaboration's potential to refine predictive models for both fall risk and disease progression. "There is a vital need for regulatory-approved digital movement endpoints in clinical trials to ensure we can accurately assess therapies for Parkinson's disease. By incorporating validated and objective measures into drug development, we can facilitate meticulous evaluations and expedite optimal treatments for patients."

Remote Monitoring and Future Directions

Looking ahead, this phase of the collaboration will focus on evaluating the usability and efficacy of the Opal data collected through remote monitoring tasks in various environments, including patients' homes. With Clario’s Mobilise-D Digital Mobility Outcomes, the project aims to improve the overall assessment of mobility and health status in Parkinson's disease patients.

For more information regarding Clario and its innovative wearable sensor technology, you can visit Clario.com.

About Clario

Clario is committed to providing endpoint data solutions to the clinical trials industry, serving pharmaceutical, biotechnology, and medical device partners for over 50 years. Boasting over 30,000 clinical trial opportunities across more than 100 countries, Clario’s offerings include comprehensive solutions such as electronic Clinical Outcome Assessments (eCOA), cardiac solutions, medical imaging, and precision motion endpoints, enabling superior clinical evidence.

About NeuroMetrology Lab

The NeuroMetrology Lab, under the direction of Professor Antoniades, is dedicated to developing objective tools to measure neurological function. Their interdisciplinary approach combines cutting-edge sensor technology and clinical neuroscience to enhance the detection, monitoring, and treatment of movement disorders like Parkinson's disease.

With the potential to change the landscape of Parkinson's research and clinical treatment, this partnership is set to make waves in the medical community as it progresses toward better patient care.